BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther 2019;50:930-9. [PMID: 31342533 DOI: 10.1111/apt.15427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Schattenberg JM. Intestinal motility: a therapeutic target for NAFLD? Lancet Gastroenterol Hepatol 2020;5:957-8. [PMID: 32805206 DOI: 10.1016/S2468-1253(20)30204-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Alqahtani SA, Schattenberg JM. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34346799 DOI: 10.1080/14737159.2021.1964958] [Reference Citation Analysis]
3 Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:592373. [PMID: 33424768 DOI: 10.3389/fendo.2020.592373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lensu S, Pekkala S. Gut Microbiota, Microbial Metabolites and Human Physical Performance. Metabolites 2021;11:716. [PMID: 34822374 DOI: 10.3390/metabo11110716] [Reference Citation Analysis]
5 O'Gorman P, Monaghan A, McGrath M, Naimimohasses S, Gormley J, Norris S. Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions. Phys Ther 2021;101:pzaa195. [PMID: 33104787 DOI: 10.1093/ptj/pzaa195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Michel M, Schattenberg JM. Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) – how are clinical trials affected? Expert Opinion on Investigational Drugs 2020;29:93-7. [DOI: 10.1080/13543784.2020.1716333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Boedecker SC, Philippi KFA, Neuberger E, Schmidt S, Pfirrmann D, Haller N, Schwarting A, Simon P, Weinmann-Menke J. Twelve-Week Internet-Based Individualized Exercise Program in Adults With Systemic Lupus Erythematosus: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2020;9:e18291. [PMID: 33141101 DOI: 10.2196/18291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Schattenberg JM. Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. Visc Med 2020;36:411-6. [PMID: 33251276 DOI: 10.1159/000507231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, Galle PR, Schattenberg JM. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatol Commun 2019;3:1472-81. [PMID: 31701071 DOI: 10.1002/hep4.1428] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
10 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Dig Dis Sci 2020;65:2112-9. [DOI: 10.1007/s10620-019-05986-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
11 Semmler G, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD/NASH: Beyond the obvious. Liver Int 2021. [PMID: 34328248 DOI: 10.1111/liv.15024] [Reference Citation Analysis]
12 Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr 2022;8:774030. [DOI: 10.3389/fnut.2021.774030] [Reference Citation Analysis]
13 Perez-Diaz-Del-Campo N, Marin-Alejandre BA, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI, Tur JA, Martinez JA, Abete I, Zulet MA. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. Eur J Nutr 2021;60:3043-57. [PMID: 33474638 DOI: 10.1007/s00394-020-02476-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 O'Gorman P, Strahan O, Ferguson D, Monaghan A, Kennedy M, Forde C, Melo AM, Doherty DG, O'Brien KK, McKiernan S, Kenny RA, Coen R, Doherty C, Bergin C, Gormley J, Norris S. Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C. J Viral Hepat 2021;28:637-50. [PMID: 33372320 DOI: 10.1111/jvh.13460] [Reference Citation Analysis]
15 Schattenberg JM, Huber Y, Kostev K. In Reply. Dtsch Arztebl Int 2021;118:271-2. [PMID: 34114550 DOI: 10.3238/arztebl.m2021.0109] [Reference Citation Analysis]
16 Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol 2021;12:e00371. [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371] [Reference Citation Analysis]
17 Erhardtsen E, Rasmussen DGK, Frederiksen P, Leeming DJ, Shevell D, Gluud LL, Karsdal MA, Aithal GP, Schattenberg JM. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. JHEP Rep 2021;3:100317. [PMID: 34466796 DOI: 10.1016/j.jhepr.2021.100317] [Reference Citation Analysis]
18 O'Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Melo AM, Ní Fhloinn D, Doherty DG, Beddy P, Finn SP, Moore JB, Gormley J, Norris S. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther 2020;52:1387-98. [PMID: 32717123 DOI: 10.1111/apt.15989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
19 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
20 Chen HW, Ferrando A, White MG, Dennis RA, Xie J, Pauly M, Park S, Bartter T, Dunn MA, Ruiz-margain A, Kim WR, Duarte-rojo A. Home-Based Physical Activity and Diet Intervention to Improve Physical Function in Advanced Liver Disease: A Randomized Pilot Trial. Dig Dis Sci 2020;65:3350-9. [DOI: 10.1007/s10620-019-06034-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
21 Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines 2021;9:145. [PMID: 33546191 DOI: 10.3390/biomedicines9020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Machado MV. Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3627-45. [PMID: 34408459 DOI: 10.2147/DMSO.S304357] [Reference Citation Analysis]
23 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019;133:2245-64. [PMID: 31742325 DOI: 10.1042/CS20190068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
24 Mak AL, Lee J, van Dijk AM, Vali Y, Aithal GP, Schattenberg JM, Anstee QM, Brosnan MJ, Zafarmand MH, Ramsoekh D, Harrison SA, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1920. [PMID: 34944736 DOI: 10.3390/biomedicines9121920] [Reference Citation Analysis]
25 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
26 Hofmann WP, Buggisch P, Schubert L, Dikopoulos N, Schwenzer J, Muche M, Felten G, Heyne R, Ingiliz P, Schmidt A, Stein K, Wedemeyer H, Berg T, Wiegand J, Lammert F, Zeuzem S, Schattenberg JM. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.JHEP Rep. 2020;2:100168. [PMID: 32964201 DOI: 10.1016/j.jhepr.2020.100168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Stine JG. Editorial: twenty minutes of moderate-to-vigorous physical activity a day keeps the NAFLD away. Aliment Pharmacol Ther 2022;55:116-7. [PMID: 34907567 DOI: 10.1111/apt.16662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Formes H, Bernardes JP, Mann A, Bayer F, Pontarollo G, Kiouptsi K, Schäfer K, Attig S, Nikolova T, Hofmann TG, Schattenberg JM, Todorov H, Gerber S, Rosenstiel P, Bopp T, Sommer F, Reinhardt C. The gut microbiota instructs the hepatic endothelial cell transcriptome. iScience 2021;24:103092. [PMID: 34622147 DOI: 10.1016/j.isci.2021.103092] [Reference Citation Analysis]
29 Carneros D, López-Lluch G, Bustos M. Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E3472. [PMID: 33198247 DOI: 10.3390/nu12113472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 O'Gorman P, Norris S. Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol 2021;8:e000568. [PMID: 34168043 DOI: 10.1136/bmjgast-2020-000568] [Reference Citation Analysis]
31 Labenz C, Toenges G, Zheng M, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gómez MR, Bugianesi E, Anstee QM, Schattenberg JM. Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2021.12.011] [Reference Citation Analysis]
32 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
33 Parry SA, Hodson L. Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review. Adv Ther 2020;37:1381-406. [PMID: 32146704 DOI: 10.1007/s12325-020-01281-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
34 Ochmann DT, Philippi KFA, Zeier P, Sandner M, Hillen B, Neuberger EWI, Ruiz de Azua I, Lieb K, Wessa M, Lutz B, Simon P, Brahmer A. Association of Innate and Acquired Aerobic Capacity With Resilience in Healthy Adults: Protocol for a Randomized Controlled Trial of an 8-Week Web-Based Physical Exercise Intervention. JMIR Res Protoc 2021;10:e29712. [PMID: 34847062 DOI: 10.2196/29712] [Reference Citation Analysis]